ICAM1 and Alzheimer disease: These ‘AD/G9a-coregulated’ entities were primarily involved in synaptic signaling, neuronal transmission and nervous system development related pathways (Fig. 7B) with 148 out of 348 members showing Aβ peptide (residues 6–28) correlated expression in the brain of AD patients including CD109, CD44, ANO6, ICAM1 and PLSCR4 (Fig. 7D, Fig. S6A and Data S1E).